Clinical efficacy and safety of Flebogammadif®, a new high-purity human intravenous immunoglobulin, in adult patients with chronic idiopathic thrombocytopenic purpura

Transfusion Medicine

Volumn 19, Issue 5, 2009, Pages 260-268

  Julia, A ^a   Kovaleva, L ^b   Loria, S ^c   Alberca, I ^d   Hernandez, F ^e   Sandoval, V ^f   Sierra, J ^g   Vidaller, A ^h   Ayguasanosa, J ⁱ   Carretero, M ⁱ  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b NATIONAL RESEARCH CENTER FOR HEMATOLOGY   (Russian Federation)

^c Botkin Hospital   (Russian Federation)

^d HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^e HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^f HOSPITAL DE LEÓN   (Spain)

^g HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^h HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

ⁱ Instituto Grifols SA   (Spain)

Author keywords

Chronic idiopathic thrombocytopenic purpura; Clinical trial; Intravenous immunoglobulins; Platelets

Indexed keywords

CORTICOSTEROID; FLEBOGAMMADIF; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ASTHENIA; BLEEDING; BLOOD PRESSURE FLUCTUATION; BRADYCARDIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; EPISTAXIS; FEMALE; FOLLOW UP; HEADACHE; HUMAN; HYPERTENSION; HYPOTENSION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; MALE; MULTICENTER STUDY; PETECHIA; REMISSION; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; THROMBOCYTE COUNT; THROMBOCYTHEMIA; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHRONIC DISEASE; DRUG TOXICITY; HEMORRHAGE; HEMOSTASIS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MIDDLE AGED; PLATELET COUNT; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; TREATMENT OUTCOME; YOUNG ADULT;

EID: 69949180812     PISSN: 09587578     EISSN: 13653148     Source Type: Journal    
DOI: 10.1111/j.1365-3148.2009.00945.x     Document Type: Article

References (22)

1. Altman, D.G., Machin, D., Bryant, T.N. & Gardner, M.J. (2000) Statistics with Confidence (ed. BM J Books) (2nd edn). Bristol.
2. Berger, M. Flebogamma 5% DIF Investigators 2007) A multicenter, prospective, open label, historically controlled clinical trial to evaluate efficacy and safety in primary immunodeficiency diseases (PID) patients of Flebogamma 5% DIF, the next generation of Flebogamma. Journal of Clinical Immunology, 27, 628 633.
3. Bussel, J.B., Eldor, A., Kelton, J.G. et al. & IGIV-C in ITP Study Group 2004) IGIV-C, a novel intravenous immunoglobulin: evaluation of safety, efficacy, mechanisms of action, and impact on quality of life. Thrombosis and Haemostasis, 91, 771 778.
4. Choi, C.W., Kim, B.S., Seo, J.H. et al. (2001) Response to high-dose intravenous immune globulin as a valuable factor predicting the effect of splenectomy in chronic idiopathic thrombocytopenic purpura patients. American Journal of Hematology, 66, 197 202.
5. Cines, D.B. & Blanchette, V.S. (2002) Immune thrombocytopenic purpura. New England Journal of Medicine, 346, 995 1008.
6. Cines, D.B. & Bussel, J.B. (2005) How I treat idiopathic thrombocytopenic purpura (ITP). Blood, 106, 2244 2251.
7. Colovic, M., Dimitrijevic, M., Sonnenburg, C., Suvajdzic, N., Donfrid, M. & Bogdanovic, A. (2003) Clinical efficacy and safety of a novel intravenous immunoglobulin preparation in adult chronic ITP. Hematology Journal, 4, 358 362.
8. EMEA 2000) Note for guidance on the clinical investigation of human normal immunoglobulin for intravenous administration (IVIg). CPMP/BPWG/388/95.
9. George, J.N., El-Harake, M.A. & Raskob, G.E. (1994) Chronic idiopathic thrombocytopenic purpura. New England Journal of Medicine, 331, 1207 1211.
10. George, J.N., El-Harake, M.A. & Aster, R.H. (1995) Thrombocytopenia due to enhanced platelet destruction by immunologic mechanism. In: Williams Hematology (5th edn) (ed. Beutler, E., Lichtmann, M.A., Boller, B.A. & Kipps, T.J. 1315 1355. McGraw Hill, New York.
11. George, J.N., Woolf, S.H., Raskob, G.E. et al. (1996) Idiopathic thrombocytopenic purpura: A practice guideline developed by explicit methods for the American Society of Hematology. Blood, 88, 3 40.
12. Imbach, P. & Kühne, T. (1998) Immune thrombocytopenia purpura (ITP). Vox Sanguinis, 74 (Suppl. 2 309 314.
13. Jorquera, J.I. (2007) Safety procedures of coagulation factors. Haemophilia, 13 (Suppl. 5 41 46.
14. Karpatkin, S. (1997) Autoimmune (idiopathic) thrombocytopenic purpura. The Lancet, 349, 1531 1536.
15. Kazatchkine, M.D. & Kaveri, S.V. (2001) Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. New England Journal of Medicine, 345, 747 755.
16. Korninger, C., Panzer, S., Graninger, W., Neumann, E., Niessner, H., Lechner, K. & Deutsch, E. (1985) Treatment of severe idiopathic thrombocytopenic purpura in adults with high-dose intravenous gammaglobulin. Scandinavian Journal of Haematology, 34, 128 132.
17. McMillan, R. (1997) Therapy for adults with refractory chronic immune thrombocytopenic purpura. Annals of Internal Medicine, 126, 307 314. (Pubitemid 27078779)
18. Newland, A.C., Burton, I., Cavenagh, J.D., Copplestone, A., Dolan, G., Houghton, J. & Reilly, T. (2001) Vigam-S, a solvent/detergent-treated intravenous immunoglobulin in idiopathic thrombocytopenic purpura. Transfusion Medicine, 11, 37 44.
19. Pierce, L.R. & Jain, N. (2003) Risk associated with the use of intravenous immunoglobulin. Transfusion Medicine Reviews, 17, 241 251.
20. Provan, D. & Newland, A. (2002) Fifty years of idiopathic thrombocytopenic purpura (ITP): management of refractory ITP in adults. British Journal of Haematology, 118, 933 944.
21. Varga, G., Volková, Z., Leibl, H. et al. (2006) Efficacy and safety of the new intravenous immunoglobulin IGIV 10% in adults with chronic idiopathic thrombocytopenic purpura. Transfusion Medicine and Hemotherapy, 33, 509 514.
22. Wolf, H.H., Davies, S.V., Borte M., et al. (2003) Efficacy, tolerability, safety and pharmacokinetics of a nanofiltered intravenous immunoglobulin: studies in patients with immune thrombocytopenic purpura and primary immunodeficiencies. Vox Sanguinis, 84, 45 53.